SIGA Technologies, Inc. Produces FDA Registration Batches of ST-246(r) Drug Product

NEW YORK, March 30, 2009 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight biowarfare pathogens, today announced that it has completed the steps needed to demonstrate its ability to manufacture commercial quantities of ST-246(r), its smallpox antiviral. The process involved producing three batches of ST-246 using FDA-established manufacturing practices. SIGA's work was funded in part by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, and the Biomedical Advanced Research and Development Authority of the U.S. Department of Health & Human Services.
MORE ON THIS TOPIC